Earnings call transcript: Implantica Q2 2026 sales rise 66% as FDA approval lifts outlook

Implantica reported that its second-quarter sales surged 66% year-over-year to EUR 717,000, driven by the FDA approval of its RefluxStop device. The device, which treats gastroesophageal reflux disease (GERD), marks a pivotal moment for the Swiss medtech company's U.S. expansion. Adjusted gross margin expanded to 94% from 90% a year earlier, demonstrating the company's ability to scale without sacrificing economics.

Management noted an operating loss of EUR 4.2 million, a 7% improvement from the previous year, while cash reserves stood at EUR 41.7 million and there was no interest-bearing debt. The company is preparing for a phased U.S. launch, with training centers, inventory, and surgeon education already in motion. Despite the small revenue base, the 66% sales growth and 94% adjusted gross margin indicate strong underlying progress.

Implantica's FDA approval and U.S. launch readiness are seen as more significant by investors than the current earnings, as they position the company for long-term commercial success.